It's past "in the works". CBD pharmaceutical grade is the most expensive and lucrative part of this market. It is also the sector of the CBD market most will be unable to participate in. Exactus has this capability due to their past experience in the biotech market. Fully vertical integration from seed to the level of pharmaceutical level CBD can reach $250,000 per acre in revenues. Of course the costs are higher in terms of seeds and or seedlings and the cost of CBD extraction which EXDI will be outsourcing. I do not expect this level of revenues in year one per acre, but will hope we achieve $100,000 per acre revenue in 2019 or 20M for the year. This equals 400M at 20x and $12 per share with 34M shares. Anything above $100,000 will be gravy imo. Also, some one time costs for the first year will imo reduce the profit margins somewhat, but then be made up next year when EXDI reaches their goal of 800-1000 acres of production. The next 18 months will be a very exciting time for all of us EXDI investors in my opinion.
Market Data 
Markets 
AI
